本季度信息
截至2025年9月30日止六个月，精优药业控股有限公司录得营收约2800万港元，同比上一财年同期（约3080万港元）下降约9%。同期净亏损约为4.59亿港元，而上年同期则实现净利润约1.01亿港元。毛利约为1227万港元，对应毛利率约43.8%，高于上年同期的38.4%。期内销售及分销费用约594万港元，同比增加约36%，主要系在竞争环境加剧背景下加大市场拓展及推广资源投入所致；管理费用约1050万港元，较上一同期的1039万港元基本持平。
业务分项
制造业务方面，期内营收约2800万港元，同比减少约280万港元。公司在成本效率优化带动下，维持了较为稳定的盈利能力，但为开拓新据点及强化市场占有率，销售投入同比上升。贸易业务方面，因处于业务开发初期及试销阶段，期内营收约为1万港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.